Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25570886 | 0.90 | ALDH1A1 (0.33) | CA12CA1CA2CA7CA14 | |
| SCHEMBL29349120 | 0.81 | — | — | |
| SCHEMBL23902103 | 0.79 | TSHR (0.42) | TSHR | |
| SCHEMBL12371957 | 0.78 | — | — | |
| SCHEMBL23806163 | 0.77 | CA12 (0.31) | CA12CA1CA2CA7CA14 | |
| SCHEMBL20621820 | 0.77 | ALDH1A1 (0.50) | CA2TSHR | |
| SCHEMBL23901191 | 0.75 | — | — | |
| SCHEMBL19262982 | 0.75 | — | — | |
| SCHEMBL5948644 | 0.75 | FDPS (0.32) | CA12CA1CA2CA7CA14 | |
| SCHEMBL5948284 | 0.75 | CA12 (0.31) | CA12CA1CA2CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11707457-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20210087184-A1 | AMINO-BENZOISOTHIAZOLE AND AMINO-BENZOISOTHIADIAZOLE AMIDE COMPOUNDS | ALCON INC. (CH) | 2021-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CA12 4583/4885CA1 4622/4885CA2 4617/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | CA12 3274/4885CA1 3255/4885CA2 4080/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CA12 4583/4885CA1 4622/4885CA2 4617/4885 |
| US-11679109-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCA2, SMARCC2 | CA12 3274/4885CA1 3255/4885CA2 4080/4885 |
| US-20210087184-A1 | AMINO-BENZOISOTHIAZOLE AND AMINO-BENZOISOTHIADIAZOLE AMIDE COMPOUNDS | ATM, MAP3K15, MAP3K3 | CA12 4873/4885CA1 4881/4885CA2 3742/4885 |
| US-11707457-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CA12 4583/4885CA1 4622/4885CA2 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.